Variable | (NÂ =Â 69) n (%) |
---|---|
PSA before prostatectomy (ng/mL), median (range) | 10.0 (0.8, 84.0) |
Resection margins | Â |
 R0 | 31 (44.9%) |
 R1 | 38 (55.1%) |
Gleason score | Â |
  ≤ 7 | 40 (58.0%) |
  ≥ 8 | 28 (40.6%) |
 missing | 1 (1,4%) |
Tumor classification | Â |
 pT2a | 4 (5.8%) |
 pT2b | 1 (1.4%) |
 pT2c | 16 (23.2%) |
 pT3a | 21 (30.4%) |
 pT3b | 26 (37.7%) |
 pT4 | 1 (1.4%) |
Lymphadenectomy performed | Â |
 No | 9 (13.0%) |
 Yes | 60 (87.0%) |
Lymphnode classification | Â |
 N0 | 51 (73.9%) |
 N1 | 18 (26.1%) |
Number of lymph nodes removed, median (range) | 13.0 (1.0, 51.0) |
Persistent PSA 4–12 weeks after prostatectomy |  |
  < 0.1 ng/mL | 46 (66.7%) |
  ≥ 0.1 ng/mL | 15 (21.7%) |
  < 0.5 ng/ml | 54 (78.3%) |
  ≥ 0.5 ng/ml | 7 (10.1%) |
 missing | 8 (11.6%) |
PSA at start of RT | Â |
  < 0.5 ng/mL | 57 (82.6%) |
  ≥ 0.5 ng/mL | 12 (17.4%) |
Age at start of RT median (range) in years | 66 (45, 78) |
Time from surgery to RT start, median (range) in months | 10.0 (1.0, 155.0) |
ECOG performance status at treatment start | Â |
 0 | 12 (17.4%) |
 1 | 57 (82.6%) |
RT technique | Â |
 Tomotherapy | 69 (100%) |
ADT during RT | Â |
 No | 46 (66.7%) |
 Yes | 23 (33.3%) |
Pelvic nodal RT | Â |
 No | 53 (76.8%) |
 Yes | 16 (23.2%) |